Advertisement


Bruce Minksy, MD's, Expert Perspective: Radiotherapy in 2015

2015 ASTRO Annual Meeting

Advertisement

ASTRO President Bruce Minsky, MD, of MD Anderson Cancer Center, talks about the goals and highlights of this year’s ASTRO Annual Meeting.



Related Videos

Breast Cancer

Robert Kuske, MD, on PROMIS Registry Results

Robert Kuske, MD, of Arizona Breast Cancer Specialists, discusses the evaluation of more than 1,300 patients with accelerated partial-breast irradiation via multicatheter interstitial brachytherapy, focusing on toxicity and cosmetic outcomes (Abstract 133).

Gynecologic Cancers

Supriya Chopra, MD, on Reducing Late Bowel Toxicity in Cervical Cancer

Supriya Chopra, MD, of Tata Memorial Hospital, discusses results of the PARCER study, which compared conventional 3D conformal radiotherapy to image-guided intensity-modulated radiotherapy in reducing bowel side effects for women with cervical cancer (Abstract 8).

Lung Cancer

Roy Decker, MD, PhD, on Chemoradiation in Elderly Patients With Limited-Stage SCLC

Roy Decker, MD, PhD, of Yale University School of Medicine, discusses a National Cancer Database analysis that showed elderly patients with limited-stage small cell lung cancer can benefit from adding concurrent radiation to chemotherapy (Abstract 1010).

Pancreatic Cancer
Hepatobiliary Cancer

Joel E. Tepper, MD, on Radiotherapy in Liver and Pancreatic Cancers

Joel E. Tepper, MD, of the University of North Carolina School of Medicine, discusses the ways in which SBRT has changed radiotherapy, as demonstrated in key studies presented at this year's meeting on stereotactic body radiotherapy for liver metastases and hepatocellular carcinoma, and borderline resectable and unresectable pancreatic tumors (Abstracts 253, 255, 351, 357).

Head and Neck Cancer
Prostate Cancer

Bruce Minsky, MD, on Clinical Trial Results: The ASCENDE-RT Trial and a Multicenter Study on Prostate Cancer

Bruce Minsky, MD, of MD Anderson Cancer Center, discusses two important papers: results from a prospective trial on quality-of-life outcomes for low-risk HPV-associated oropharyngeal squamous cell carcinoma, and a prostate cancer radiation therapy study (Abstracts 3, 4).

Advertisement

Advertisement




Advertisement